This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (26)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Kazuhiko Takehara; Kanako Kikuchi; Yoshihisa Soma; Atsuyuki Igarashi; Yasumasa Ishibashi
Department of Dermatology Faculty of Medicine University of Tokyo 7-3-1 Hongo Bunkyo-ku, Tokyo 113, Japan

Arch Dermatol. 1990;126(10):1368-1369.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Localized scleroderma differs from systemic sclerosis because of the difference in the distribution of skin sclerosis and the lack of Raynaud's phenomenon, acrosclerosis, and internal involvement. In localized scleroderma, the lesions are usually limited to the skin and to the subcutaneous tissue beneath the cutaneous lesions. However, it has been suggested that the disease has an immunologic basis because the serum samples of patients frequently contain antinuclear antibody (ANA). Recent reports on ANAs by indirect immunofluorescence methods using monolayer cultured cells showed greater frequencies than those by previous standard tests using frozen tissue sections. We first reported that 72% of the patients with localized scleroderma have positive ANAs when HeLa cells served as the test substrate.¹ Recently, Falanga et al^2-4 have reported elevated levels of anti-single-stranded DNA (anti-ss-DNA) antibody in localized scleroderma. They have also shown a positive correlation between anti-ss-DNA antibody and joint contracture . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?